MindMed Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Updates
Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product ...
Johnson & Johnson: No More Tears, Just Gains In Intra-Cellular Acquisition
JNJ's $14B acquisition of ITCI bolsters its portfolio with Caplyta, showing strong sales and patent protection until 2033.
Neurocrine Biosciences initiates trial of VMAT2 inhibitor in healthy adults
The therapy joins another VMAT2 inhibitor, NBI-1065890, which is undergoing assessment by the company in Phase I trials.
MedPage Today on MSN13h
ADHD Drug Recall; Alcohol and Sports Gambling; Deprescribing Benzodiazepines
Glenmark Pharma recalled 1.48 million bottles of the generic attention deficit-hyperactivity disorder (ADHD) drug atomoxetine ...
Axsome Therapeutics, Inc.: Axsome Therapeutics Settles Sunosi (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA
Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders ...
Neuronetics, Inc. (NASDAQ:STIM) Q4 2024 Earnings Call Transcript
Q4 2024 Earnings Call Transcript March 4, 2025 Neuronetics, Inc. misses on earnings expectations. Reported EPS is $-0.33 EPS, expectations were $-0.26. Operator: Good day, and thank you for standing ...
NetraMark Holdings Inc.: Netramark Unveils AI Driven Insights for Major Depressive Disorder and Schizophrenia at ISCTM Conference
TORONTO, ON / ACCESS Newswire / March 5, 2025 / NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE:AIAI)(OTCQB:AINMF)(Frankfurt:8TV) a generative AI software leader in clinical trial analytic ...